HC 010
Alternative Names: HC-010Latest Information Update: 25 Apr 2024
Price :
$50 *
At a glance
- Originator HC Biopharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Mar 2024 Phase-I clinical trials in Solid tumours (Recurrent, Monotherapy, Metastatic disease, Late-stage disease) in China (IV) (NCT06307925)
- 13 Mar 2024 HC 010 is available for licensing as of 13 Mar 2024. http://www.hcbiopharma.com/en/collaboration#partner
- 13 Mar 2024 Preclinical trials in Solid tumours in China (IV)